Can Quantitative MRI After cTACE Help Predict Survival ?

Status Completed

Clinical Trial Summary

Transcatheter arterial chemoembolization (TACE) is a widely accepted palliative therapy for the treatment of HCC. Palliative means that it does not cure the disease prolongs your life and improves quality of life. During TACE, a mixture of chemotherapy drugs is combined with an oil called lipiodol. Lipiodol has a role as both drug carrier and embolic agent (a material that blocks blood flow to tumors). The lipiodol/chemotherapy mixture is injected into an artery (blood vessel) directly supplying blood to a HCC tumor.

Lipiodol is made up of fat and water which can be seen on MRI. Therefore, MRI can be used to quantify the amount of lipiodol delivered to the HCC tumors.

In this study, the investigators want to see if patient survival is related to the amount of lipiodol delivered to HCC tumors.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02173119
Study type	Observational
Source	Medical College of Wisconsin
Contact
Status	Completed
Phase
Start date	August 2014
Completion date	March 7, 2018

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03007212` - Outcome of Transarterial Chemo-embolization (TACE) in Hepatocellular Carcinoma Patients With Partial Portal Vein Thrombosis	Phase 4
Terminated	`NCT03236649` - The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects	Phase 3
Withdrawn	`NCT04044326` - The Safety and Efficacy of Spherical Microwave Ablation for the Treatment of Malignant Liver Tumors	N/A
Recruiting	`NCT04687969` - Multimodal Machine Learning Characterization of Solid Tumors
Completed	`NCT02562755` - Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone	Phase 3
Withdrawn	`NCT02406508` - Sequential Melphalan for Use With Hepatic Delivery System Treatment Followed by Sorafenib in Patients With Unresectable HCC	Phase 2
Completed	`NCT01972672` - The Phase II Study of Icaritin in Patients With Advanced Hepatocellular Carcinoma	Phase 2
Completed	`NCT01247298` - A Pilot Study of Trans Arterial Chemoembolization (TACE), Followed by Stereotactic Radiation Therapy (SBRT) for Patients With Hepatocellular Carcinoma	Phase 0
Completed	`NCT03735628` - An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors	Phase 1
Completed	`NCT02188901` - Contrast (Sonazoid)-Enhanced US as a Screening Tool for Hepatocellular Carcinoma in Cirrhosis: An Exploratory Cross-sectional Study	N/A
Active, not recruiting	`NCT04522908` - Dose Escalation Study of Cabozantinib for Advanced HCC Patients With Preserved Liver Function	Phase 2
Terminated	`NCT01433016` - Detection of Hepatocellular Carcinoma (HCC) With Octanoate Breath ID Test Compared to MRI	Phase 2
Withdrawn	`NCT04465734` - A Clinical Study to Compare the Efficacy and Safety of HLX10 in Combination With HLX04 Versus Sorafenib as the First-line Treatment in Patients With Locally Advanced or Metastatic HCC	Phase 3
Recruiting	`NCT05057013` - HMBD-001 in Advanced HER3 Positive Solid Tumours	Phase 1/Phase 2
Active, not recruiting	`NCT03753659` - IMMULAB - Immunotherapy With Pembrolizumab in Combination With Local Ablation in Hepatocellular Carcinoma (HCC)	Phase 2
Terminated	`NCT03144661` - An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies	Phase 1
Not yet recruiting	`NCT01821482` - A Study of DC-CIK to Treat Hepatocellular Carcinoma	Phase 2
Completed	`NCT03516071` - A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCC	Phase 2
Completed	`NCT01761266` - A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma	Phase 3
Not yet recruiting	`NCT06345001` - A First-in-Human Study to Learn About How BAY3630942 is Distributed and Processed Inside the Body When Given After BAY3547922 and How Safe it is in People With Liver Cancer	Phase 1